{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:32Z","timestamp":1756902152546,"version":"3.44.0"},"reference-count":26,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:sec>\n          <jats:title>OBJECTIVES<\/jats:title>\n          <jats:p>This study aims to describe the effectiveness of low initial alprostadil dosages to maintain a patent ductus arteriosus (PDA) in infants with ductal-dependent congenital heart disease (DDCHD). Secondary objectives were to describe any adverse drug events, describe prescribing trends, describe ductus arteriosus diameter changes, and compare the safety and efficacy of very low and low initial alprostadil dosage regimens.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>METHODS<\/jats:title>\n          <jats:p>This retrospective observational cohort study at the British Columbia\u2019s Women\u2019s and Children\u2019s Hospital neonatal intensive care unit and pediatric intensive care unit examined neonates admitted with DDCHD who received alprostadil to maintain ductal patency. Very low\u2013dose alprostadil (less than 0.01 mcg\/kg\/min) versus low-dose alprostadil (equal to or greater than 0.01 mcg\/kg\/min) was examined. Effectiveness was defined as survival and infants not requiring a resuscitation event (cardiac arrest, cardiogenic shock, code blue, extracorporeal life support, requirement for emergent cardiac surgery, and respiratory acidosis). Adverse drug events with a Naranjo score of 3 or more were included.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>RESULTS<\/jats:title>\n          <jats:p>Alprostadil was effective for 88% of patients, with no difference between the very low\u2013dose and low-dose groups. Of the 75 patients included, 25 received very low\u2013dose alprostadil. Adverse drug events were common (51%) with neonates in the low-dose group experiencing more apnea and pyrexia than neonates in the very low\u2013dose group.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>CONCLUSIONS<\/jats:title>\n          <jats:p>Alprostadil therapy was effective in maintaining the PDA in neonates with DDCHD with low-dosage regimens. Adverse drug events were common with both dosage regimens; however, the very low dosage appeared to have less apnea and pyrexia.<\/jats:p>\n        <\/jats:sec>","DOI":"10.5863\/1551-6776-29.1.37","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T12:01:45Z","timestamp":1707739305000},"page":"37-44","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Alprostadil for Ductal Patency"],"prefix":"10.5863","volume":"29","author":[{"given":"Caitlin M.","family":"Gordon","sequence":"first","affiliation":[{"name":"Lower Mainland Pharmacy Services (CMG), Vancouver General Hospital, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason T.","family":"Tan","sequence":"additional","affiliation":[{"name":"Pharmacy Department (JTT, RRC), BC Women\u2019s and Children\u2019s Hospital, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxane R.","family":"Carr","sequence":"additional","affiliation":[{"name":"Pharmacy Department (JTT, RRC), BC Women\u2019s and Children\u2019s Hospital, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"key":"i2331-348X-29-1-37-b01","series-title":"Pathophysiology: The Biologic Basis for Disease in Adults and Children","author":"McCance","year":"2014","unstructured":"McCance\n              KL\n            , HuetherSE. Pathophysiology: The Biologic Basis for Disease in Adults and Children. Elsevier Health Sciences; 2014."},{"issue":"5","key":"i2331-348X-29-1-37-b02","series-title":"Arq Bras Cardiol","first-page":"666","article-title":"Mortality for critical congenital heart diseases and associated risk factors in newborns: a cohort study","volume":"111","author":"Lopes","year":"2018","unstructured":"Lopes\n              SA\n            , Guimar\u00e3esIC, CostaSF, \n          . Mortality for critical congenital heart diseases and associated risk factors in newborns: a cohort study. Arq Bras Cardiol. 2018;111(5):666\u2013673."},{"issue":"5","key":"i2331-348X-29-1-37-b03","series-title":"Pediatrics","first-page":"e1502","article-title":"Temporal trends in survival among infants with critical congenital heart defects","volume":"131","author":"Oster","year":"2013","unstructured":"Oster\n              ME\n            , LeeKA, HoneinMA, \n          . Temporal trends in survival among infants with critical congenital heart defects. Pediatrics. 2013;131(5):e1502\u2013e1508."},{"issue":"4","key":"i2331-348X-29-1-37-b04","series-title":"Pediatr Cardiol","first-page":"205","article-title":"Prevalence, treatment, and outcome of heart disease in live-born children: a prospective analysis of 91,823 live-born children","volume":"10","author":"Samanek","year":"1989","unstructured":"Samanek\n              M\n            , SlavikZ, ZborilovaB, \n          . Prevalence, treatment, and outcome of heart disease in live-born children: a prospective analysis of 91,823 live-born children. Pediatr Cardiol. 1989;10(4):205\u2013211."},{"year":"2020","author":"Prostin VR Sterile Solution [package insert]","key":"i2331-348X-29-1-37-b05","unstructured":"Prostin VR Sterile Solution [package insert]\n          . Quebec, Canada: Pfizer Canada; 2020."},{"issue":"3","key":"i2331-348X-29-1-37-b06","series-title":"Pediatrics","first-page":"325","article-title":"Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia","volume":"59","author":"Heymann","year":"1977","unstructured":"Heymann\n              MA\n            , RudolphAM. Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia. Pediatrics. 1977;59(3):325\u2013329."},{"issue":"10","key":"i2331-348X-29-1-37-b07","series-title":"South Med J","first-page":"1238","article-title":"Pharmacologic dilatation of the ductus arteriosus with prostaglandin E1 in infants with congenital heart disease","volume":"71","author":"Graham","year":"1978","unstructured":"Graham\n              TP\n              Jr\n            , AtwoodGF, BoucekRJJr. Pharmacologic dilatation of the ductus arteriosus with prostaglandin E1 in infants with congenital heart disease. South Med J. 1978;71(10):1238\u20131241."},{"issue":"1","key":"i2331-348X-29-1-37-b08","series-title":"Circulation","first-page":"169","article-title":"Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities","volume":"59","author":"Heymann","year":"1979","unstructured":"Heymann\n              MA\n            , BermanWIJr, RudolphAM, WhitmanVI. Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities. Circulation. 1979;59(1):169\u2013173."},{"issue":"9","key":"i2331-348X-29-1-37-b09","series-title":"Acta Paediatr","first-page":"1303","article-title":"Prostaglandin therapy for ductal patency: how long is too long?","volume":"97","author":"Brodlie","year":"2008","unstructured":"Brodlie\n              M\n            , ChaudhariM, HasanA. Prostaglandin therapy for ductal patency: how long is too long?Acta Paediatr. 2008;97(9):1303\u20131304."},{"issue":"4","key":"i2331-348X-29-1-37-b10","series-title":"Crit Care Med","first-page":"185","article-title":"Congenital heart disease requiring maintenance of ductus arteriosus in critically ill newborns admitted at a tertiary neonatal intensive care unit","volume":"2","author":"Cucerea","year":"2016","unstructured":"Cucerea\n              M\n            , SimonM, MoldovanE, \n          . Congenital heart disease requiring maintenance of ductus arteriosus in critically ill newborns admitted at a tertiary neonatal intensive care unit. Crit Care Med. 2016;2(4):185\u2013191."},{"issue":"1","key":"i2331-348X-29-1-37-b11","series-title":"J Crit Care","first-page":"174-e1","article-title":"Accuracy of clinical diagnosis and decision to commence intravenous prostaglandin E1 in neonates presenting with hypoxemia in a transport setting","volume":"25","author":"Shivananda","year":"2010","unstructured":"Shivananda\n              S\n            , KirshJ, WhyteHE, \n          . Accuracy of clinical diagnosis and decision to commence intravenous prostaglandin E1 in neonates presenting with hypoxemia in a transport setting. J Crit Care. 2010;25(1):174-e1."},{"issue":"11","key":"i2331-348X-29-1-37-b12","series-title":"Arch Dis Child","first-page":"1025","article-title":"Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease","volume":"60","author":"Silove","year":"1985","unstructured":"Silove\n              ED\n            , RobertsDG, De GiovanniJV. Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease. Arch Dis Child. 1985;60(11):1025\u20131030."},{"issue":"3","key":"i2331-348X-29-1-37-b13","series-title":"Eur Heart J","first-page":"377","article-title":"Chrome congestive heart failure: study of low dosage \u00adprostaglandin\u2013usages and complications","volume":"15","author":"Singh","year":"1994","unstructured":"Singh\n              GK\n            , FongLV, SalmonAP, KeetonBR. Chrome congestive heart failure: study of low dosage \u00adprostaglandin\u2013usages and complications. Eur Heart J. 1994;15(3):377\u2013381."},{"issue":"4 suppl","key":"i2331-348X-29-1-37-b14","series-title":"Pediatr Crit Care Med","first-page":"131","article-title":"Evaluation of infusion protaglandin (PGE2) versus infusion prostaglandin e1 (PGE1) in management of duct-dependent pulmonary circulation congenital heart disease","volume":"15","author":"Abidin","year":"2014","unstructured":"Abidin\n              AZ\n            , KhalidF, MSaidR. Evaluation of infusion protaglandin (PGE2) versus infusion prostaglandin e1 (PGE1) in management of duct-dependent pulmonary circulation congenital heart disease. Pediatr Crit Care Med. 2014;15(4 suppl):131."},{"issue":"9","key":"i2331-348X-29-1-37-b15","series-title":"Eur J Pediatr","first-page":"700","article-title":"Evaluation of low dose prostaglandin E 1 treatment for ductus dependent congenital heart disease","volume":"154","author":"Kramer","year":"1995","unstructured":"Kramer\n              HH\n            , SommerM, RammosS, KrogmannO. Evaluation of low dose prostaglandin E 1 treatment for ductus dependent congenital heart disease. Eur J Pediatr. 1995;154(9):700\u2013707."},{"issue":"2","key":"i2331-348X-29-1-37-b16","series-title":"Arch Dis Child Fetal Neonatal Ed","first-page":"F117","article-title":"Transporting newborn infants with suspected duct dependent congenital heart disease on low-dose prostaglandin E1 without routine mechanical ventilation","volume":"92","author":"Carmo","year":"2007","unstructured":"Carmo\n              KA\n            , BarrP, WestM, \n          . Transporting newborn infants with suspected duct dependent congenital heart disease on low-dose prostaglandin E1 without routine mechanical ventilation. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F117\u2013F119."},{"issue":"1","key":"i2331-348X-29-1-37-b17","series-title":"Cardiol Young","first-page":"56","article-title":"Efficacy of very low-dose prostaglandin E1 in duct-dependent congenital heart disease","volume":"25","author":"Yucel","year":"2015","unstructured":"Yucel\n              IK\n            , CevikA, BulutMO, \n          . Efficacy of very low-dose prostaglandin E1 in duct-dependent congenital heart disease. Cardiol Young. 2015;25(1):56."},{"issue":"10","key":"i2331-348X-29-1-37-b18","series-title":"Pharmacotherapy","first-page":"e227","article-title":"Effectiveness of alprostadil dose titration in neonates with congenital heart disease","volume":"32","author":"Buck","year":"2012","unstructured":"Buck\n              M\n            , LimS, AttridgeJ. Effectiveness of alprostadil dose titration in neonates with congenital heart disease. Pharmacotherapy. 2012;32(10):e227."},{"issue":"2","key":"i2331-348X-29-1-37-b19","series-title":"Pediatr Neonatol","first-page":"102","article-title":"Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation","volume":"54","author":"Huang","year":"2013","unstructured":"Huang\n              FK\n            , LinCC, HuangTC, \n          . Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Pediatr Neonatol. 2013;54(2):102\u2013106."},{"key":"i2331-348X-29-1-37-b20","series-title":"J Pediatr","first-page":"237","article-title":"Prostaglandin E1-induced periostitis and reversibility with discontinuation","volume":"189","author":"Badheka","year":"2017","unstructured":"Badheka\n              A\n            , PrakashPB, AllareddyV. Prostaglandin E1-induced periostitis and reversibility with discontinuation. J Pediatr. 2017;189:237."},{"issue":"5","key":"i2331-348X-29-1-37-b21","series-title":"Circulation","first-page":"893","article-title":"Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease","volume":"64","author":"Lewis","year":"1981","unstructured":"Lewis\n              AB\n            , FreedMD, HeymannMA, \n          . Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease. Circulation. 1981;64(5):893\u2013898."},{"key":"i2331-348X-29-1-37-b22","series-title":"BC Children\u2019s Hospital Pediatric Drug Dosage Guidelines","first-page":"14","author":"Alprostadil","year":"2019","unstructured":"Alprostadil\n          . In: EsauR, ed. BC Children\u2019s Hospital Pediatric Drug Dosage Guidelines. 7th ed. Vancouver, Canada: Children\u2019s and Women\u2019s Health Centre Department of Pharmacy. 2019:14. http:\/\/www.pedmed.org\/DrugApp\/index.html"},{"issue":"2","key":"i2331-348X-29-1-37-b23","series-title":"J Clin Pharm Ther","first-page":"239","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","unstructured":"Naranjo\n              CA\n            , BustoU, SellersEM, \n          . A method for estimating the probability of adverse drug reactions. J Clin Pharm Ther. 1981;30(2):239\u2013245."},{"issue":"2","key":"i2331-348X-29-1-37-b24","series-title":"J Biomed Inform","first-page":"377","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","unstructured":"Harris\n              PA\n            , TaylorR, ThielkeR, \n          . Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u2013381."},{"key":"i2331-348X-29-1-37-b25","article-title":"Sample size to estimate a proportion or apparent prevalence with specified precision","author":"Epitools","year":"2020","unstructured":"Epitools\n          . Sample size to estimate a proportion or apparent prevalence with specified precision. 2020. Accessed September 4, 2020. https:\/\/epitools.ausvet.com.au\/oneproportion"},{"issue":"3","key":"i2331-348X-29-1-37-b26","series-title":"J Pediatr","first-page":"481","article-title":"Administration of prostaglandin E1 in neonates with critical congenital cardiac defects","volume":"93","author":"Lewis","year":"1978","unstructured":"Lewis\n              AB\n            , TakahashiM, LuriePR. Administration of prostaglandin E1 in neonates with critical congenital cardiac defects. J Pediatr. 1978;93(3):481\u2013485."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/1\/article-p37.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/1\/37\/3325977\/i2331-348x-29-1-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/29\/1\/article-p37.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/29\/1\/article-p37.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:52:18Z","timestamp":1747356738000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/1\/article-p37.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":26,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.1.37","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2024]]}}}